Please login to the form below

Not currently logged in
Email:
Password:

Novartis India leader responds to Glivec patent rejection

The head of Novartisí Indian operations has responded to the Glivec cancer drug patent ruling.

The head of Novartisí Indian operations has responded to the Glivec cancer drug patent ruling.

"India is not open for business," said Rajit Shahani in an interview with the Wall Street Journal website, Livemint.com.

In early August 2007, the court issued its decision to uphold the Indian Patents Act and dismissed Novartis' writ petition challenging constitutionality of Section 3(d), regarding incremental innovation.

The Swiss company filed an appeal after its patent application for Glivec was rejected. The drug has been granted patent in approximately 40 countries, including China; but was denied in India in 2006. Novartis challenged the section that it claims does not permit patent to medicines with safety advantages.

"Indian pharma companies and multinational drug makers push for changes in opposite directions on matters such as price control, data protection and definition of patentability," accused Shahani.

He concluded: "Novartis is likely not to appeal the decision. Our actions have advanced this essential debate in India, now itís up to the relevant political leaders and groups to work together to strengthen Indiaís patent law."

24th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics